SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13D - Tempus AI, Inc. (0001717115) (Filed by)

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in

4 - Tempus AI, Inc. (0001717115) (Reporting)

Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

William Blair downgraded Tempus AI from Outperform to Mkt Perform

TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously

Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00

Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00

Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously

BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously

Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00

BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00

Stifel initiated coverage of Tempus AI with a rating of Buy and set a new price target of $45.00

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus' existing network Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured

The kidSAFE certified app will offer kids and parents an alternative to gaming, social media and passive video consumption, reclaiming time for reading and creative play CHICAGO, March 5, 2025 /PRNewswire/ -- Wendy, a new kind of story company, has launched a children's story-building toolbox app that provides a safe and engaging story-building experience, helping children unlock their creativity and immersing them in endless possibilities for imaginative reading adventures. With kids' digital activity time rapidly increasing while literacy rates decrease, the Wendy app offers an engaging story-telling experience for kids to rediscover their love of reading. With the Wendy app, children par

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. Year-over-year revenue growth accelerated to 35.8% in the fourth quarter of 2024 Gross profit growth accelerated to 49.7% in the fourth quarter of 2024, led by Data and services Ended the year with $940 million in Total Remaining Contract Value and 140% net revenue retention Closed the acquisition of Ambry Genetics on February 3, 2025 Increases revenue guidance to $1.24 billion for 2024 and expect full year 2025 Adjusted EBITDA of approximately $5 million, an improvement

Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help clinicians support more informed treatment-making decisions. The Next platform will analyze clinical data from mBC patients treated in certain centers and notify clinicians when ESR1 testing is missing at disease progression. CHICAGO and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, and the Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics com

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Monday, March 3. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provi

Ares Management Corporation (NYSE:ARES) ("Ares"), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. (NASDAQ:TEM) ("Tempus"), a technology company leading the adoption of AI to advance precision medicine and patient care. The financing is intended to support Tempus' previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million. Founded in 2015, Tempus is bringing data

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the conference on Monday, March 3, 2025. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentified FL data library in Lens - Tempus' data analytics platform - through which researchers may derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes. IFLI is committed

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary – Weeks after the monumental $500-billion announcement of Project Stargate, which includes aims to transform healthcare, a growing number of health executives are seeing the promise of Artificial Intelligence (AI) in their industry. A recent poll from Deloitte found that 40% of health execs say generative AI (genAI) pays off for their businesses. Early in 2025, it's becoming clearer that genAI is revolutionizing diagnostics, enhancing treatment options, and personalizing patient care. Beyond Stargate's big players, a growing number of innovator

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i